Taylor Cram

AlivaMab Biologics provides fully integrated solutions for biologics drug discovery through our continuously expanding platform of innovative capability modules. Our most recent additions to our capability modules include drug discovery for fully human single-domain VH, common light chain multispecific antibodies, and TCR mimic antibodies. AMB’s customizable capability modules include target validation, protein- and cell-based tool engineering and production, sophisticated functional assay development and execution, discovery of binding domains using Ablexis’ suite of AlivaMab Mouse strains, kinetic and epitope characterization, protein and antibody engineering across a breadth of novel biologic drug modalities, full-depth developability assessment, antibody optimization, and production up to medium scale. AMB’s partners also gain from the team’s direct experience and know-how in the discovery and development of biologics drugs across various modalities. Partners may select to work with AMB across the full spectrum of capability modules or to pick and choose across them. AlivaMab Biologics sets its partners’ biologics programs on the path to success with the fastest and most de-risked solutions through discovery and development.